03.20.24 -- The Future Of mRNA For Cancer Treatment

To prepare allogeneic, or "donor-derived," CAR T cells for commercial scale, you must consider scaleup, aseptic processing, single-use systems, facility design, starting material, supply chain, and logistics.

Learn about the distinction between gene therapy and gene editing, as well as the therapeutic potential of CRISPR treatments and the challenges associated with clinical trials and commercialization.

Discover how leveraging Little’s Law to quantify metrics that otherwise would be causing confusion and process interruption can help to reduce wait times and deliver materials on time and within budget.

By utilizing a CDMO's capabilities, pharmaceutical companies can focus on their core competencies and accelerate the development and delivery of life-saving therapies to patients.

Companies often turn to CDMOs to bring vector-based products to market, so it's important that they know how to assess a CDMO’s capabilities to help them achieve their goals.

Finding a CDMO partner with the requisite expertise, materials, external supply chain, and capacity is key to maximizing a therapy’s chances of commercial success.